Back to today’s briefing

Story perspectives

New Study: Dapagliflozin Boosts Diabetes Remission Rates

1/25/2025

50 12

Summary

Story summary

A groundbreaking study in China reveals that pairing dapagliflozin, an SGLT-2 inhibitor, with calorie restriction can dramatically enhance diabetes remission and metabolic health in adults battling type 2 diabetes and obesity. Remarkably, nearly half of those on dapagliflozin achieved remission, far surpassing the placebo group, paving the way for a hopeful new strategy in diabetes management.

1 of 1

Story summary

A groundbreaking study in China reveals that pairing dapagliflozin, an SGLT-2 inhibitor, with calorie restriction can dramatically enhance diabetes remission and metabolic health in adults battling type 2 diabetes and obesity. Remarkably, nearly half of those on dapagliflozin achieved remission, far surpassing the placebo group, paving the way for a hopeful new strategy in diabetes management.